MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why GLSI Stock surged +3.77% Today — RQD Quant Desk Flash
$19.00 +3.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $19.09
Greenwich LifeSciences Inc. (GLSI) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $278.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $19.09 (+0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GLSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY GLSI SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)
FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 53 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$16.53-12% Next Q
33
Q2 (-2Q)Grade E$14.55+10.2% Next Q
36
Q3 (-1Q)Grade E$16.03+18.5% Next Q
38
CurrentGrade D-$19.00-7.2% Hist 90D α
41
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GLSI Turnaround Squeeze
While GLSI currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.75) and Max Pain ($19.95) forces dealer call-delta covering toward $35.80.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GLSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GLSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GLSI Stock surged +3.77% Today — RQD Quant Desk Flash
Greenwich LifeSciences Inc. (GLSI) surged +3.77% to $19.00, trading at 43% of its 52-week range ($7.78 – $34.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 43% of its 52-week range ($7.78 – $34.1) with RSI-14 at 53 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $19.00 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GLSI Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLSI)
- ✓Walkthrough of GLSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GLSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.56%▲ RESISTANCE BREAKOUT
2026-10-30O $18.47H $19.00L $17.04C $19.00VOL 174.6K
RES: $18.11SUP: $13.98SMA50: $16.75SMA200: $21.54
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GLSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GLSI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GLSI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GLSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLSI)
Health Care Rank #611 of 1016
⚔️ RCKT vs GLSI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GLSI vs. RCKT, LRMR, LYEL, BIOA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenwich LifeSciences Inc. (GLSI) ranks #611 by composite RQD confidence (41/100, grade D-) and #528 by equity capitalization ($278.9M). Within this direct 5-issuer industry benchmark cohort, GLSI leads on earnings valuation at N/A trailing P/E, while GLSI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with GLSI at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GLSI
ACTIVE
Greenwich LifeSciences Inc. | D- | 41/100 | — | — | -35.0% | +3.77% | $278.9M | Benchmark Subject |
| RCKT Rocket Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -1.55% | $278.8M | /rckt-vs-glsi → |
| LRMR Larimar Therapeutics Inc. | D | 50/100 | — | — | -35.0% | +5.12% | $277.4M | /lrmr-vs-glsi → |
| LYEL Lyell Immunopharma Inc. | D- | 38/100 | — | — | -35.0% | +3.43% | $277.0M | /lyel-vs-glsi → |
| BIOA BioAge Labs Inc. | D | 44/100 | — | — | -35.0% | 0.00% | $272.6M | /bioa-vs-glsi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799788In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenwich LifeSciences Inc. (GLSI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$9.9M, and free cash flow of -$9.9M (-36.4% YoY). On the balance sheet, GLSI closed FY2025 with $6.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$19.4M | -$9.9M | -$9.9M | $6.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$17.4M | -$7.3M | -$7.3M | $4.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.9M | -$6.5M | -$6.5M | — | — |
3. GLSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Greenwich LifeSciences Inc. (NASDAQ: GLSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $19.00 (+3.77% 1D, market cap $278.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLSI ranks #611 in composite RQD confidence.
How does GLSI compare to RCKT and LRMR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GLSI carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RCKT (Rocket Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $278.8M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, GLSI leads on earnings multiple (N/A) while GLSI leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GLSI?
Per GLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799788), Greenwich LifeSciences Inc. generated $0 in revenue, -$19.4M in net income, and -$9.9M in free cash flow against $6.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GLSI trading relative to its 50-day, 200-day, and 52-week technical levels?
GLSI last traded at $19.00 (+3.77% on volume of 124,128 shares), positioning the stock +13.43% above its 50-day simple moving average ($16.75) and -11.79% below its 200-day simple moving average ($21.54). Across its 52-week range of $7.78 to $34.10, GLSI sits at the 42.6% percentile with a 14-day RSI of 53.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.62 to $21.38).
GLSI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GLSI stock moving today?
Why GLSI Stock surged +3.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.